Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. develops clinical-stage small molecule precision medicines for cancer and genetic disease. The company uses its Dynamo® platform, which combines computational and experimental approaches to drug protein targets that have been intractable or inadequately addressed.
Recurring RLAY news centers on zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor studied in HR+/HER2- metastatic breast cancer and PI3Kα-driven vascular anomalies. Company updates also cover pipeline programs for NRAS-driven solid tumors and Fabry disease, clinical and regulatory data presentations, operating results, capital-structure matters, license or collaboration agreements, and governance developments.
Relay Therapeutics (Nasdaq: RLAY) reported Q2 2026 results highlighted by progress for lead PI3Kα inhibitor zovegalisib and a strengthened balance sheet. The company selected zovegalisib plus atirmociclib as the go-forward triplet regimen for first-line (1L) HR+/HER2-, PI3Kα-mutated breast cancer and plans a Phase 3 1L trial in endocrine-sensitive patients in early 2027, subject to regulatory feedback. In heavily pre-treated, CDK4/6-experienced median third-line breast cancer, the triplet showed a 44% objective response rate at unoptimized doses. Initial Phase 1/2 ReInspire data in PIK3CA-driven vascular anomalies showed 60% volumetric responses at 12 weeks and symptomatic improvement in nearly all patients, with a safety profile supporting potential chronic use. Relay continued the Phase 3 ReDiscover-2 2L breast cancer trial and Phase 1/2 RLY-8161 trial in NRAS-mutant tumors. Q2 cash, cash equivalents and investments were $910.9 million, boosted by approximately $316 million gross proceeds from a May 2026 follow-on offering, and the company expects runway into 2029. Revenue was $0.4 million, R&D expenses $76.5 million, G&A expenses $14.7 million and net loss $83.7 million ($0.41 per share).
Relay Therapeutics (Nasdaq: RLAY), a clinical-stage small molecule precision medicine company focused on therapies for cancer and genetic diseases, plans to report its second quarter 2026 financial results and corporate highlights after U.S. market close on Thursday, August 6, 2026.
The announcement outlines the timing of the upcoming financial disclosure and related corporate update, allowing investors and analysts to prepare for Relay Therapeutics’ next scheduled earnings communication.
Relay Therapeutics (Nasdaq: RLAY) announced that management will participate in two investor fireside chats in June 2026.
Events include the 2026 Jefferies Global Healthcare Conference on June 3 at 12:45 p.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 at 8:40 a.m. ET. Both will be webcast live, with replays available for 30 days.
Relay Therapeutics (Nasdaq: RLAY) priced an underwritten public offering of 22,916,667 common shares at $12.00 per share. Underwriters have a 30-day option to buy up to 3,437,500 additional shares.
Gross proceeds are expected to be about $275 million, before fees, with closing expected on or about May 22, 2026, subject to customary conditions.
Relay Therapeutics (Nasdaq: RLAY) has launched an underwritten public offering of $175 million of common stock. The company plans to grant underwriters a 30-day option to buy up to an additional 15% of the shares.
All shares are to be sold by Relay Therapeutics under an effective Form S-3ASR shelf registration. Jefferies, TD Cowen, Goldman Sachs and Guggenheim Securities are joint bookrunners, with Raymond James as lead manager. The deal’s timing, size and terms remain subject to market conditions.
Relay Therapeutics (Nasdaq: RLAY) reported initial Phase 2 ReInspire data for zovegalisib in PIK3CA-driven vascular anomalies. Among 20 response-evaluable adults/adolescents, 60% showed volumetric lesion response at 12 weeks, rising to 65% after data cut-off, with 89% investigator- and 79% patient-reported clinical improvement and an interim safety profile supporting chronic dosing at optimized regimens.
Relay Therapeutics (Nasdaq: RLAY) reported Q1 2026 results and program updates on May 5, 2026. Key items: FDA Breakthrough Therapy designation for zovegalisib in PIK3CA‑mutant HR+/HER2‑ advanced breast cancer; 11.1‑month median PFS in CDK4/6‑experienced patients; Phase 3 ReDiscover‑2 ongoing; selected zovegalisib+atirmociclib triplet for 1L with Phase 3 planned in early 2027.
Cash, cash equivalents and investments were $642.1M at March 31, 2026; Q1 revenue was $3.0M; net loss was $73.3M ($0.41/share).
Relay Therapeutics (Nasdaq: RLAY) will report first quarter 2026 financial results and corporate highlights on Tuesday, May 5, 2026 after U.S. market close. The company is a clinical-stage small molecule precision medicine firm focused on oncology and genetic-disease therapies.
Relay Therapeutics (Nasdaq: RLAY)/b) reported clinical data supporting advancement of into a planned Phase 3 frontline trial for PIK3CA‑mutated, HR+/HER2‑ metastatic breast cancer, targeting initiation in early 2027 pending regulatory feedback.
Key data: 44% ORR (15/34 measurable patients) in median third‑line, 3% zovegalisib discontinuation, 40% grade 3+ TRAE rate, and a pharmacokinetic interaction increasing zovegalisib exposure ~2.5‑fold. Pfizer will supply atirmociclib for the trial.
Relay Therapeutics (Nasdaq: RLAY) will present initial clinical and preclinical data for zovegalisib (RLY-2608) in vascular anomalies at the ISSVA World Congress 2026 in Philadelphia, May 19-22, 2026.
The company expects to report clinical data on approximately 20 efficacy-evaluable patients in a Late Breaking Abstract on May 20, 2026, and will present preclinical murine-model results showing lesion regression with minimal hyperinsulinemia on May 22, 2026. Presentations will be posted on the company website at session start times.